Form 4: BioAge Labs Director James Healy Granted 22,000 Stock Options

BioAge Labs, Inc. Director and 10% Owner James Healy was granted 22,000 stock options with an exercise price of $4.44 per share, vesting over the next year.

Summary

• James Healy, a Director and 10% Owner of BioAge Labs, Inc. (BIOA), was granted 22,000 stock options.
• The stock options have an exercise price of $4.44 per share.
• The grant date for these options was June 5, 2025.
• The options will vest on the earlier of the next annual meeting of the Issuer's stockholders or the one-year anniversary of the grant date (June 5, 2025), subject to Mr. Healy's continued service to the Issuer.
• The options have an expiration date of June 4, 2035.
• Following this transaction, James Healy beneficially owns 22,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: Slightly positive as it aligns director's interests with shareholders and is a standard incentive mechanism, indicating continued commitment.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• It indicates continued commitment and retention of a key director and 10% owner within the company.

Future Outlook

The grant of stock options to Director James Healy, subject to continued service and vesting conditions, indicates an expectation of his ongoing contribution to BioAge Labs, Inc. and aligns his future financial interests with the company's performance.

Management Comments

• While no direct quotes are provided, the grant of stock options to Director James Healy reflects the company's compensation strategy to incentivize and retain key personnel.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages to align management incentives with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard form of equity compensation for directors and executives across various industries, including biotech.
• The specific number of options (22,000) and exercise price ($4.44) would typically be benchmarked against peer companies of similar market capitalization and stage of development, such as other clinical-stage biotech firms focused on aging research, to ensure competitive and performance-aligned compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with long-term shareholder value creation.
• Employees: While not directly impacting all employees, it reflects the company's approach to executive compensation and retention.

Next Steps

• The stock options granted to James Healy are subject to vesting, which will occur on the earlier of the next annual meeting of stockholders or the one-year anniversary of the grant date (June 5, 2025), contingent on his continued service to the Issuer.

Key Dates

Keywords

BioAge Labs, BIOA, Stock Option, Insider Transaction, Director Compensation, Equity Grant, Form 4, Beneficial Ownership